当前位置: X-MOL 学术J. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
The Journal of Urology ( IF 5.9 ) Pub Date : 2021-08-27 , DOI: 10.1097/ju.0000000000002190
David D'Andrea 1 , Peter C Black 2 , Homayoun Zargar 2, 3 , Colin P Dinney 4 , Francesco Soria 5 , Michael S Cookson 6 , Jeffrey S Montgomery 7 , Wassim Kassouf 8 , Marc A Dall'Era 9 , Srikala S Sridhar 10 , John S McGrath 11 , Jonathan L Wright 12 , Andrew C Thorpe 13 , Jeff M Holzbeierlein 14 , Diego M Carrión 15 , Ettore Di Trapani 16 , Trinity J Bivalacqua 17 , Scott North 18, 19 , Daniel A Barocas 20 , Yair Lotan 21 , Petros Grivas 22, 23 , Andrew J Stephenson 4 , Bas W van Rhijn 24 , Siamak Daneshmand 25 , Philippe E Spiess 26 , Shahrokh F Shariat 1, 21, 27, 28, 29 , 7, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
Affiliation  

To investigate the pathologic response rates and survival associated with 3 versus 4 cycles of cisplatin-based NAC in patients with cT2-4N0M0 MIBC.

中文翻译:

确定肌肉浸润性膀胱癌患者的最佳新辅助化疗周期数。

研究 cT2-4N0M0 MIBC 患者 3 与 4 周期基于顺铂的 NAC 相关的病理缓解率和生存率。
更新日期:2021-08-27
down
wechat
bug